CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 51 - 60 of 886
Study Number Lead Group Study Title CIRB Study Status
10026 ETCTN A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Adult CIRB - Early Phase Emphasis Available to Open
10335 ETCTN A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Adult CIRB - Early Phase Emphasis Available to Open
ADVL1515 COG A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors Pediatric CIRB Available to Open
10273 ETCTN A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
10272 ETCTN A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
10061 ETCTN A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10246 ETCTN A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Adult CIRB - Early Phase Emphasis Available to Open
10031 ETCTN A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer Adult CIRB - Early Phase Emphasis Available to Open
ADVL1615 COG A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors Pediatric CIRB Available to Open
ADVL1416 COG A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors Pediatric CIRB Available to Open
Displaying 51 - 60 of 886